Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01979393
Other study ID # EORTC-62113-55115
Secondary ID 2013-000762-11UC
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date February 2015
Est. completion date May 2024

Study information

Verified date February 2024
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread. Therefore, we want to find out whether taking cabozantinib after treatment with surgery and chemotherapy is effective and safe for patients who responded or had stable disease after their chemotherapy. All participants will receive 4-6 cycles of standard chemotherapy. Those with stabilization or response to the standard chemotherapy will be split into 2 groups (cabozantinib or placebo).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 58
Est. completion date May 2024
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who are suitable for treatment with doxorubicin +/- ifosfamide and fall within one of the following patient populations: • HGUS, HGESS, HGLMS and HG adenosarcoma - FIGO stage II and stage III : if adjuvant chemotherapy is proposed - FIGO stage IV: if first line chemotherapy is proposed - Metastatic: diagnosed with disease relapse after local treatment for primary tumor - at least 18 years old - written informed consent - Central pathological confirmation: Histological evidence of HGUS, HGESS, HGLMS and HG adenosarcoma - Non-progressive patients (CR, PR, SD) at the end of the first line treatment (standard chemotherapy consisting of 4 to 6 cycles of anthracyclines alone or in combination with ifosfamide) - WHO/ECOG performance status 0-2 - Adequate organ and bone marrow function within 3 days prior to the first dose of study treatment (Cabozantinib/placebo) - Clinically normal cardiac function - Women of child bearing potential must have a negative serum/urine pregnancy test within 3 days prior to the first dose of study treatment - Adequate birth control measures Exclusion Criteria: - low-grade ESS, leiomyosarcoma (low or intermediate), carcinosarcoma, low-grade adenosarcoma, rhabdomyosarcoma (alveolar or embryonal) and soft tissue PNET of uterus/cervix. - contraindications to cabozantinib - not able to swallow and retain oral tablets - planned use of chemotherapy, radiation therapy, radionuclide treatment, small molecule tyrosine kinase inhibitor or hormonal therapy, and any other investigational agent (Cabozantinib/placebo) during the treatment period - concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment - patient with poorly controlled hypertension defined at baseline as blood pressure >150/90 - patients who have suffered a cerebrovascular accident at any time in the past, patients who have suffered a transient ischemic attack in the past 6 months, patients who have suffered a deep venous thrombosis (DVT) or a pulmonary embolism in the past 6 months - Gastrointestinal disorders - patients with radiographic evidence of cavitating pulmonary lesion(s) - patients with tumor in contact with, invading or encasing any major blood vessels - patients evidence of tumor invading the GI tract - evidence of active bleeding or bleeding diathesis - hemoptysis = 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment - signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment - clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment - prior major surgery or trauma within 6 weeks prior to first dose of study drug and any wound, fracture, or ulcer should be completely healed - concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450 3A4/5

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cabozantinib

Placebo


Locations

Country Name City State
France Institut Bergonie Bordeaux
France Institut Bergonie Bordeaux
France Centre Leon Berard Lyon
France Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau Nantes
Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Netherlands Academisch Medisch Centrum at University of Amsterdam Amsterdam
Spain Hospital General Vall D'Hebron Barcelona
Spain Hospital Universitario San Carlos Madrid
United Kingdom Cambridge University Hospital NHS - Addenbrookes Hospital Cambridge
United Kingdom NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital Glasgow
United Kingdom Leeds Teaching Hospitals NHS Trust - St. James's University Hospital Leeds
United Kingdom Royal Marsden Hospital London
United Kingdom University College London Hospitals NHS Foundation Trust - University College Hospital London
United Kingdom Nottingham University Hospitals NHS Trust - City Hospital Nottingham
United Kingdom Oxford University Hospitals NHS Trust - Churchill Hospital Oxford

Sponsors (3)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC Gynecologic Oncology Group, NHS Greater Glasgow and Clyde

Countries where clinical trial is conducted

France,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) The primary endpoint is PFS rate at 4 months after randomization to cabozantinib or placebo 3.5 years from first patient in
Secondary Progression free survival 3.5 years from first patient in
Secondary Overall survival 3.5 years from first patient in
Secondary Response rate 3.5 years from first patient in
Secondary Duration of response to cabozantinib 3.5 years from first patient in
Secondary Response rate to anthracycline-based chemotherapy for the patients with measurable disease 3.5 years from first patient in
Secondary Assessment of global health status/QoL scale The primary health-related quality of life endpoint that is considered of interest for this study is the global health status/QoL scale 3.5 years from first patient in
Secondary Occurence of Adverse Events This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting. 3.5 years from first patient in
See also
  Status Clinical Trial Phase
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Recruiting NCT00162721 - The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Phase 3
Completed NCT01806350 - Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors N/A
Recruiting NCT05881967 - Molecular Mechanism Study of Uterine Sarcoma
Active, not recruiting NCT06244251 - Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids N/A
Completed NCT00020267 - Vaccine Therapy in Treating Patients With Metastatic Cancer Phase 1
Recruiting NCT04224467 - The Application of Real-Time Near-infrared Imaging in Gynecological Surgery N/A
Completed NCT01303094 - Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma Phase 2
Available NCT03493165 - Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)